Farmas USA (7684/16988)

#61465

Re: Farmas USA

14/04/15 05:35

SNTA. Me gusta más el medio y largo Plazo en proreal, a ver pa donde tira:

Juanma SNTA

#61466

Re: Farmas USA

14/04/15 05:51

ADXS: Se eleva el precio objetivo a los 25 dólares:

http://www.smarteranalyst.com/2015/04/13/h-c-wainwright-pounds-the-table-on-advaxis-inc/

#61467

Re: Farmas USA

framus_morrigan

14/04/15 05:57

XOMA corto plazo y opciones el 17 Abril

#61468

Re: Farmas USA

framus_morrigan

14/04/15 05:59

AMRN , opciones el 17 y el 24 Abril

Es alcista pero con la sombra del veredicto acechandonos ... es impredecible

#61469

Re: Farmas USA

framus_morrigan

14/04/15 06:01

THLD SEMANAL , opciones el 17

me gusta, superada la MM200 en 4,36 y datos de Hypoxin para el AACR el proximo fin de semana

Los 4,89-4,91 son vitales segun lo veo

#61470

Re: Farmas USA

framus_morrigan

14/04/15 06:11

SUNTRUST https://docs.google.com/file/d/0B1gB2YESBJV7N0hZSEs2Z01odjQ/edit

CEO John Thero & VP of Finance Mike Farrell in meetings with investors in Boston.

AMRN is expected to attract partners like Eddingpharm (China) for Russia, EU, LatAm, and the Middle East.

Maintain Buy & $6 PT.

AMRN

#61471

Re: Farmas USA

14/04/15 06:36

CAMBRIDGE, Mass. and EXTON, Pa., April 13, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 1:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York City.

IDRA

#61472

Re: Farmas USA

Zokatira96

14/04/15 06:37

Hepatitis B is the world's most common liver virus, having chronically infected an estimated 240 million people worldwide, according to the World Health Organization.
Robust Pipeline:

DSMB safety review of Heplisav-B in July, as well as from hopefully promising data related to the HBV-23 study in late 2015 to early 2016.
Out of the five analysts covering Dynavax, the highest price target is $60 and the overall average sits at $30 a share.
http://seekingalpha.com/article/3064536-dynavax-technologies-positive-catalysts-right-around-the-corner?
app=1&auth_param=ft8lg:1aiomt3:623e48a52c6c2ef257045525913fa6f5&uprof=37
---------------

DVAX.-Dynavax Technology…¡Esto se puede calentar y mucho!…(Actu…08/04/2015)
http://nasdaqlandia.com/dvax-dynavax-technology-esto-se-puede-calentar-y-mucho-actu-08042015.html?utm_campaign=nasdaqlandia-20150413&utm_medium=email&utm_source=acumbamail
---------
Todo esto lo sabemos desde hace 3 años, veo pumpeo en toda regla para solpar la dilucion que corresponde pues no veo logico un M.Cap de 653M con apenas Shares 28 M